China Pet Veterinary Diets - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The china pet veterinary diets market size was USD 217.70 million in 2025, which is projected to reach USD 236.20 million in 2026, and USD 355.20 million by 2031, growing at a CAGR of 8.50% from 2026 to 2031. This report is Segmented by Sub Product (Diabetes, Renal, Urinary Tract Disease, Digestive Sensitivity, Oral Care Diets, Derma Diets, Obesity Diets, and Others), by Pets (Cats, Dogs, and Other Pets), and by Distribution Channel (Convenience Stores, Online Channel, Specialty Stores, and More). The Market Forecasts are Provided in Terms of Value in USD and Volume in Metric Tons.

China Pet Veterinary Diets Market Trends and Insights

Rising Veterinary Diagnosis of Chronic Pet Conditions

The demand for prescription diets in the China pet veterinary diet market is closely linked to the incidence of diagnosed diseases rather than general pet ownership. According to the 2026 China Pet Industry White Paper, feline lower urinary tract syndrome accounted for 10.2% of all cat clinic visits in 2025, while gastroenteritis was the leading reason for dog consultations at 6.9%. Additionally, the 2025 China Pet Medical Food Industry White Paper highlighted that urban pets aged 7 years and older reached 30 million in 2025, a demographic with significant exposure to chronic renal disease and prolonged dietary management needs. This is important because older pets are more likely to remain on therapeutic diets for extended periods after diagnosis. In 2024, diagnosis-linked penetration stood at 24.4% for dogs and 17.8% for cats, indicating potential for further improvement in treatment adoption. Furthermore, annual per-pet spending increased by 27.9% in the same year, reflecting higher expenditures by owners who adopt sustained care practices. As diagnostic capabilities improve across urban clinics, the China pet veterinary diet market is projected to grow through an expanding active patient base rather than relying solely on price increases.

Pet Humanization and Therapeutic Premiumization

The growing trend of treating pets as family members is driving increased investment in clinical nutrition in the China pet veterinary diet market. According to Xinhua, China’s pet population exceeded the number of children under 4 in 2024, marking a significant shift in household spending priorities. During Tmall’s Double Eleven event in 2024, sales of prescription and functional pet food grew year over year by more than 100%, while sales of specialized health products surged by 500%. This trend indicates that premium health nutrition is transitioning from a niche purchase to a more widely accepted aspect of pet care. Additionally, pet owners are increasingly opting for formulas that support long-term condition management rather than focusing solely on short-term symptom relief. This shift expands the potential market for therapeutic diets, which bridge the gap between medicine and daily feeding. Consequently, the China pet veterinary diet market benefits not only from a growing pet population but also from a rising proportion of owners committed to maintaining structured health routines following a diagnosis.

Premium Pricing Versus Mainstream Pet Food

Price remains a significant barrier to broader access in the China pet veterinary diet market. Prescription veterinary diets in China are typically priced 4 to 8 times higher than equivalent-weight mainstream kibble, limiting adoption primarily to higher-income urban households. This pricing disparity is particularly impactful in lower-tier cities, where pet ownership is increasing, but discretionary spending remains limited. Prior to the implementation of the May 2026 standard, some imported therapeutic products faced formal distribution barriers, leading to parallel imports and increased counterfeit risks in certain markets. While the new regulatory framework has reduced confusion, it has not addressed the premium cost difference between clinical diets and standard pet food. Virbac’s local manufacturing initiative in Changzhou highlights the potential of domestic production as a pricing strategy in this category. Unless more brands develop methods to narrow the price gap, the China pet veterinary diet market is anticipated to continue growing more rapidly in top-tier cities than in the broader mass market.

Other drivers and restraints analyzed in the detailed report include:

• Online Veterinary Refill and O2O Fulfillment Expansion
• Rising Cat Ownership and Feline-Specific Nutrition Need
• Regulatory Approval and Label Compliance Friction

Segment Analysis

Renal accounted for 24.0% of sub-product revenue in 2025, making them the largest category within the China pet veterinary diet market. This dominance of renal formulas is attributed to the aging pet population and the prevalence of kidney-related conditions in both cats and dogs. According to the 2025 China Pet Medical Food Industry White Paper, the incidence of chronic kidney disease in cats aged 6 years and older was 30%, while renal failure in dogs aged 10 years and older exceeded 25%. Digestive Sensitivity contributed 19% of revenue in 2025, followed by Obesity Diets at 17% and Diabetes at 12%. The remaining market share was distributed among urinary tract disease diets, oral care diets, derma diets, and other veterinary diets. This distribution within the China pet veterinary diet market highlights that chronic disease feeding is not limited to a single condition. Furthermore, the 2026 China Pet Industry White Paper reported that gastroenteritis was the leading cause of veterinary consultations for dogs and the second most common for cats, underscoring the broad clinical demand for digestive sensitivity diets during the forecast period.

The Digestive Sensitivity segment is projected to grow at a CAGR of 9.5% from 2026 to 2031, outpacing the overall growth of the China pet veterinary diet market. Renal diets, obesity diets, and diabetes-related diets are also anticipated to expand during the forecast period, indicating that the largest condition categories are growing concurrently rather than competing with one another. The national standard implemented in May 2026 establishes nutritional thresholds for therapeutic categories such as renal and obesity formulas, which is anticipated to enhance quality consistency across the market. This is significant as clinical confidence increases when formula claims are supported by clear specifications. Additionally, it enables established brands to maintain their market position against less precisely positioned alternatives. Farmina’s 2025 launch of VetLife Dog Treats, which included condition-specific stock-keeping units for renal function, gastrointestinal health, and struvite management, highlights the category's expansion beyond complete diets into related formats. In the China pet veterinary diet market, this diversification can increase wallet share within each condition category without altering the core disease mix.

Complete Report Scope:

• By Sub Product
  • Diabetes
  • Digestive Sensitivity
  • Oral Care Diets
  • Renal
  • Urinary Tract Disease
  • Obesity Diets
  • Derma Diets
  • Other Veterinary Diets
• By Pets
  • Cats
  • Dogs
  • Other Pets
• By Distribution Channel
  • Convenience Stores
  • Online Channel
  • Specialty Stores
  • Supermarkets/Hypermarkets
  • Other Channels

List of Companies Covered in this Report:

• Mars, Incorporated
• Nestlé S.A. (Purina)
• Colgate-Palmolive Company (Hill’s Pet Nutrition, Inc.)
• General Mills, Inc. (Blue Buffalo)
• The J. M. Smucker Company
• Farmina Pet Foods
• Virbac
• Boehringer Ingelheim Animal Health
• Elanco Animal Health Incorporated
• ADM
• Affinity Petcare S.A.
• PLB International
• Spectrum Brands Holdings, Inc.
• Wellness Pet Company
• Dechra Pharmaceuticals PLC

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support